The Immunobiology of Systemic Sclerosis

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 2, 2008, Pages 132-160

  Gu, Y Stephanie ^a   Kong, James ^a   Cheema, Gurtej S ^a   Keen, Carl L ^a   Wick, Georg ^b   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

apoptosis; autoimmunity; collagen deposition; cytokine; fibrosis; systemic sclerosis

Indexed keywords

CHEMOKINE; COLLAGEN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD VESSEL INJURY; CELL FUNCTION; CELL INTERACTION; CYTOKINE PRODUCTION; CYTOTOXICITY; EPIGENETICS; FIBROBLAST; GENE EXPRESSION; HUMAN; IMMUNOBIOLOGY; LUNG FIBROSIS; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

FEMALE; FIBROBLASTS; HUMANS; MALE; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 46849119322     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.10.010     Document Type: Article

References (262)

1. Jimenez S.A., and Christner P.J. Murine animal models of systemic sclerosis. Curr Opin Rheumatol 14 (2002) 671-680
2. Van de Water J., Jimenez S.A., and Gershwin M.E. Animal models of scleroderma: contrasts and comparisons. Int Rev Immunol 12 (1995) 201-216
3. Prescott R.J., Freemont A.J., Jones C.J., Hoyland J., and Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166 (1992) 255-263
4. Sgonc R., Gruschwitz M.S., Boeck G., Sepp N., Gruber J., and Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43 (2000) 2550-2562
5. Sgonc R., Gruschwitz M.S., Dietrich H., Recheis H., Gershwin M.E., and Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98 (1996) 785-792
6. Kalogerou A., Gelou E., Mountantonakis S., Settas L., Zafiriou E., and Sakkas L. Early T-cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64 (2005) 1233-1235
7. Mavilia C., Scaletti C., Romagnani P., Carossino A.M., Pignone A., Emmi L., et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151 (1997) 1751-1758
8. Giacomelli R., Matucci-Cerinic M., Cipriani P., Ghersetich I., Lattanzio R., Pavan A., et al. Circulating Vδ1+ T-cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41 (1998) 327-334
9. Kräling B.M., Maul G.G., and Jimenez S.A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63 (1995) 48-56
10. Seibold J.R., Giorno R.C., and Claman H.N. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum 33 (1990) 1702-1709
11. 3) and mast cells in the pathogenesis of scleroderma. Clin Rheumatol 22 (2003) 189-195
12. Claman H.N., Giorno R.C., and Seibold J.R. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 34 (1991) 1495-1501
13. Majewski S., Hunzelmann N., Johnson J.P., Jung C., Mauch C., Ziegler-Heitbrock H.W., et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 97 (1991) 667-671
14. Koch A.E., Kronfeld-Harrington L.B., Szekanecz Z., Cho M.M., Haines G.K., Harlow L.A., et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 61 (1993) 239-246
15. Gruschwitz M.S., and Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor α in the early disease stage. Arthritis Rheum 40 (1997) 540-550
16. + T-cell numbers decrease in systemic sclerosis. Clin Exp Immunol 139 (2005) 551-557
17. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45 (2006) 694-702
18. Ihn H., Sato S., Fujimoto M., Kikuchi K., Kadono T., Tamaki K., et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36 (1997) 1270-1275
19. Sfikakis P.P., Tesar J., Baraf H., Lipnick R., Klipple G., and Tsokos G.C. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68 (1993) 88-92
20. Scharffetter K., Lankat-Buttgereit B., and Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 18 (1988) 9-17
21. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100 (2003) 12319-12324
22. Kessler-Becker D., Krieg T., and Eckes B. Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop. Biochem J 379 (2004) 351-358
23. Kessler D., Dethlefsen S., Haase I., Plomann M., Hirche F., Krieg T., et al. Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J Biol Chem 276 (2001) 36575-36585
24. Harrison N.K., Myers A.R., Corrin B., Soosay G., Dewar A., Black C.M., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144 (1991) 706-713
25. Wells A.U., Lorimer S., Majumdar S., Harrison N.K., Corrin B., Black C.M., et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 8 (1995) 266-271
26. Domagala-Kulawik J., Hoser G., Doboszynska A., Kawiak J., and Droszcz W. Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. Respir Med 92 (1998) 1295-1301
27. Hussein M.R., Hassan H.I., Hofny E.R., Elkholy M., Fatehy N.A., Abd Elmoniem A.E., et al. Alterations of mononuclear inflammatory cells. CD4/CD8+ T-cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 58 (2005) 178-184
28. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Choi J., Xiao H.Q., et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T-cells from scleroderma patients. Arthritis Rheum 48 (2003) 2262-2274
29. Stummvoll G.H., Aringer M., Smolen J.S., Koller M., Kiener H.P., Steiner C.W., et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39 (2000) 1341-1350
30. Ercole L.P., Malvezzi M., Boaretti A.C., Utiyama S.R., and Rachid A. Analysis of lymphocyte subpopulations in systemic sclerosis. J Investig Allergol Clin Immunol 13 (2003) 87-93
31. Riccieri V., Parisi G., Spadaro A., Scrivo R., Barone F., Moretti T., et al. Reduced circulating natural killer T-cells and γ/δ T-cells in patients with systemic sclerosis. J Rheumatol 32 (2005) 283-286
32. Holcombe R.F., Baethge B.A., Wolf R.E., Betzing K.W., and Stewart R.M. Natural killer cells and γδ T-cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. Ann Rheum Dis 54 (1995) 69-72
33. Linsen L., Somers V., and Stinissen P. Immunoregulation of autoimmunity by natural killer T-cells. Hum Immunol 66 (2005) 1193-1202
34. Kojo S., Adachi Y., Keino H., Taniguchi M., and Sumida T. Dysfunction of T-cell receptor AV24AJ18+. BV11+ double-negative regulatory natural killer T-cells in autoimmune diseases. Arthritis Rheum 44 (2001) 1127-1138
35. +T-cells in the peripheral blood of patients suffering from rheumatic diseases. Rheumatology (Oxford) 45 (2006) 1477-1484
36. Carding S.R., and Egan P.J. γδ T-cells: functional plasticity and heterogeneity. Nat Rev Immunol 2 (2002) 336-345
37. Aljurf M., Ezzat A., and Om M. Emerging role of γδ T-cells in health and disease. Blood Rev 16 (2002) 203-206
38. Kahaleh M.B., Fan P.S., and Otsuka T. γδ receptor bearing T-cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 91 (1999) 188-195
39. Reveille J.D., Solomon D.H., and The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49 (2003) 399-412
40. Corrin B., Butcher D., McAnulty B.J., Dubois R.M., Black C.M., Laurent G.J., et al. Immunohistochemical localization of transforming growth factor-β1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 24 (1994) 145-150
41. Veeraraghavan S., Renzoni E.A., Jeal H., Jones M., Hammer J., Wells A.U., et al. Mapping of the immunodominant T-cell epitopes of the protein topoisomerase I. Ann Rheum Dis 63 (2004) 982-987
42. Hu P.Q., Oppenheim J.J., Medsger Jr. T.A., and Wright T.M. T-cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 26 (2006) 258-267
43. Warrington K.J., Nair U., Carbone L.D., Kang A.H., and Postlethwaite A.E. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 8 (2006) R136
44. McKown K.M., Carbone L.D., Bustillo J., Seyer J.M., Kang A.H., and Postlethwaite A.E. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43 (2000) 1054-1061
45. Postlethwaite A.E., Furst D.E., Wong W.K., and Clements P. Oral tolerance (OT) induction to type I collagen (CI) significantly reduces the skin score in patients with diffuse systemic sclerosis (SSc) with late-phase disease. Results of a NIAMS/NIAD multicenter phase II placebo-controlled double blind clinical trial. Arthritis Rheum 52 (2005) 109-128
46. Marie I., Cordel N., Lenormand B., Hellot M.F., Levesque H., Courtois H., et al. Clonal T-cells in the blood of patients with systemic sclerosis. Arch Dermatol 141 (2005) 88-89
47. Dereure O., Gubler B., Bessis D., Guillot B., Guilhou J.J., Clot J., et al. The presence of dominant T-cell clones in peripheral blood of patients with collagen vascular disorders: a prospective study of 97 cases. Br J Dermatol 154 (2006) 445-449
48. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., and Platsoucas C.D. Oligoclonal T-cell expansion in the skin of patients with systemic sclerosis. J Immunol 168 (2002) 3649-3659
49. De Palma R., Del Galdo F., Lupoli S., Altucci P., Abbate G., and Valentini G. Peripheral T-lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 144 (2006) 169-176
50. Yurovsky V.V., Wigley F.M., Wise R.A., and White B. Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48 (1996) 84-97
51. Tiev K.P., Abriol J., Burland M.C., Antonelli D., Klatzmann D., Cabane J., et al. T-cell repertoire in patients with stable scleroderma. Clin Exp Immunol 139 (2005) 348-354
52. + γδ T-cells in systemic sclerosis patients. J Immunol 153 (1994) 881-891
53. Zhou X., Tan F.K., Xiong M., Milewicz D.M., Feghali C.A., Fritzler M.J., et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 167 (2001) 7126-7133
54. Tan F.K., Hildebrand B.A., Lester M.S., Stivers D.N., Pounds S., Zhou X., et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 52 (2005) 865-876
55. Hénault J., Tremblay M., Clément I., Raymond Y., and Senécal J.L. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 50 (2004) 3265-3274
56. Kuwana M., Medsger Jr. T.A., and Wright T.M. Highly restricted TCR-αβ usage by autoreactive human T-cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol 158 (1997) 485-491
57. Chizzolini C., Parel Y., De Luca C., Tyndall A., Akesson A., Scheja A., et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 48 (2003) 2593-2604
58. Chizzolini C., Rezzonico R., Ribbens C., Burger D., Wollheim F.A., and Dayer J.M. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T-cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 41 (1998) 2039-2047
59. Chizzolini C., Parel Y., Scheja A., and Dayer J.M. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res Ther 8 (2005) R10
60. Brouty-Boyé D., Pottin-Clémenceau C., Doucet C., Jasmin C., and Azzarone B. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 30 (2000) 914-919
61. Fukasawa C., Kawaguchi Y., Harigai M., Sugiura T., Takagi K., Kawamoto M., et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 33 (2003) 2792-2800
62. + T-lymphocytes of systemic sclerosis patients. J Autoimmun 15 (2000) 61-66
63. Allanore Y., Borderie D., Meune C., Lemaréchal H., Weber S., Ekindjian O.G., et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 64 (2005) 481-483
64. Atamas S.P., Luzina I.G., Dai H., Wilt S.G., and White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 168 (2002) 1139-1145
65. Sempowski G.D., Chess P.R., and Phipps R.P. CD40 is a functional activation antigen and B7-independent T-cell costimulatory molecule on normal human lung fibroblasts. J Immunol 158 (1997) 4670-4677
66. van Kooten C., and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67 (2000) 2-17
67. Yamakage A., Kikuchi K., Smith E.A., LeRoy E.C., and Trojanowska M. Selective upregulation of platelet-derived growth factor α receptors by transforming growth factor β in scleroderma fibroblasts. J Exp Med 175 (1992) 1227-1234
68. Doucet C., Brouty-Boyé D., Pottin-Clémenceau C., Canonica G.W., Jasmin C., and Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 101 (1998) 2129-2139
69. Jelaska A., and Korn J.H. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43 (2000) 2230-2239
70. Prelog M., Scheidegger P., Peter S., Gershwin M.E., Wick G., and Sgonc R. Diminished transforming growth factor β2 production leads to increased expression of a profibrotic procollagen α2 type I messenger RNA variant in embryonic fibroblasts of UCD-200 chickens, a model for systemic sclerosis. Arthritis Rheum 52 (2005) 1804-1811
71. Sato S., Fujimoto M., Hasegawa M., and Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B-cells and diminished but activated memory B-cells. Arthritis Rheum 50 (2004) 1918-1927
72. Famularo G., Giacomelli R., Alesse E., Cifone M.G., Morrone S., Boirivant M., et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 29 (1989) 59-63
73. Cepeda E.J., and Reveille J.D. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 16 (2004) 723-732
74. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., and Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165 (2000) 6635-6643
75. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., and Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120 (2003) 542-547
76. Svegliati Baroni S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
77. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280 (2005) 36474-36482
78. Sambo P., Baroni S.S., Luchetti M., Paroncini P., Dusi S., Orlandini G., et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44 (2001) 2653-2664
79. Servettaz A., Tamby M.C., Guilpain P., Reinbolt J., Garcia de la Peña-Lefebvre P., Allanore Y., et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol 120 (2006) 212-219
80. Worda M., Sgonc R., Dietrich H., Niederegger H., Sundick R.S., Gershwin M.E., et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 48 (2003) 2605-2614
81. Nguyen V.A., Sgonc R., Dietrich H., and Wick G. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). J Autoimmun 14 (2000) 143-149
82. Carvalho D., Savage C.O., Black C.M., and Pearson J.D. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97 (1996) 111-119
83. Chizzolini C., Raschi E., Rezzonico R., Testoni C., Mallone R., Gabrielli A., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46 (2002) 1602-1613
84. Ronda N., Gatti R., Giacosa R., Raschi E., Testoni C., Meroni P.L., et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum 46 (2002) 1595-1601
85. Asano N., Fujimoto M., Yazawa N., Shirasawa S., Hasegawa M., Okochi H., et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165 (2004) 641-650
86. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109 (2002) 1453-1462
87. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169 (2006) 954-966
88. Kasturi K.N., Hatakeyama A., Murai C., Gordon R., Phelps R.G., and Bona C.A. B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J Autoimmun 10 (1997) 505-517
89. Ingegnoli F., Trabattoni D., Saresella M., Fantini F., and Clerici M. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 108 (2003) 21-28
90. Cipriani P., Fulminis A., Pingiotti E., Marrelli A., Liakouli V., Perricone R., et al. Resistance to apoptosis in circulating α/β and γ/δ T-lymphocytes from patients with systemic sclerosis. J Rheumatol 33 (2006) 2003-2014
91. Kessel A., Rosner I., Rozenbaum M., Zisman D., Sagiv A., Shmuel Z., et al. Increased CD8+ T-cell apoptosis in scleroderma is associated with low levels of NF-κB. J Clin Immunol 24 (2004) 30-36
92. Bordron A., Dueymes M., Levy Y., Jamin C., Leroy J.P., Piette J.C., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101 (1998) 2029-2035
93. Kuwano K., Hagimoto N., Kawasaki M., Yatomi T., Nakamura N., Nagata S., et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104 (1999) 13-19
94. Maeyama T., Kuwano K., Kawasaki M., Kunitake R., Hagimoto N., Matsuba T., et al. Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 17 (2001) 180-189
95. Hagimoto N., Kuwano K., Nomoto Y., Kunitake R., and Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16 (1997) 91-101
96. Hagimoto N., Kuwano K., Miyazaki H., Kunitake R., Fujita M., Kawasaki M., et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 17 (1997) 272-278
97. Borges V.M., Falcão H., Leite-Júnior J.H., Alvim L., Teixeira G.P., Russo M., et al. Fas ligand triggers pulmonary silicosis. J Exp Med 194 (2001) 155-164
98. Aoshiba K., Yasui S., Tamaoki J., and Nagai A. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 162 (2000) 695-700
99. Gorelik L., and Flavell R.A. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2 (2002) 46-53
100. Letterio J.J., and Roberts A.B. Regulation of immune responses by TGF-β. Annu Rev Immunol 16 (1998) 137-161
101. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425 (2003) 577-584
102. Gruschwitz M., Müller P.U., Sepp N., Hofer E., Fontana A., and Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis?. J Invest Dermatol 94 (1990) 197-203
103. Querfeld C., Eckes B., Huerkamp C., Krieg T., and Sollberg S. Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma. J Dermatol Sci 21 (1999) 13-22
104. Kulozik M., Hogg A., Lankat-Buttgereit B., and Krieg T. Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86 (1990) 917-922
105. Kubo M., Ihn H., Yamane K., and Tamaki K. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 29 (2002) 2558-2564
106. Pannu J., Gore-Hyer E., Yamanaka M., Smith E.A., Rubinchik S., Dong J.Y., et al. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 50 (2004) 1566-1577
107. 3 mRNA transcripts in normal and fibrotic human lung. Thorax 56 (2001) 549-556
108. Ludwicka A., Ohba T., Trojanowska M., Yamakage A., Strange C., Smith E.A., et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22 (1995) 1876-1883
109. Meloni F., Caporali R., Marone Bianco A., Paschetto E., Morosini M., Fietta A.M., et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 111-118
110. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138 (2004) 540-546
111. Sato S., Hasegawa M., and Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27 (2001) 140-146
112. Atamas S.P., and White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 14 (2003) 537-550
113. Mattila L., Airola K., Ahonen M., Hietarinta M., Black C., Saarialho-Kere U., et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 110 (1998) 416-421
114. Yamane K., Ihn H., Asano Y., Jinnin M., and Tamaki K. Antagonistic effects of TNF-α on TGF-β signaling through down-regulation of TGF-β receptor type II in human dermal fibroblasts. J Immunol 171 (2003) 3855-3862
115. Doucet C., Brouty-Boyé D., Pottin-Clemenceau C., Jasmin C., Canonica G.W., and Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 10 (1998) 1421-1433
116. 1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 271 (1996) 17779-17784
117. Yamane K., Ihn H., Kubo M., and Tamaki K. Increased transcriptional activities of transforming growth factor β receptors in scleroderma fibroblasts. Arthritis Rheum 46 (2002) 2421-2428
118. Ihn H., Yamane K., Kubo M., and Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 44 (2001) 474-480
119. Kikuchi K., Kadono T., Ihn H., Sato S., Igarashi A., Nakagawa H., et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-β1. J Invest Dermatol 105 (1995) 128-132
120. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., and Tamaki K. Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 52 (2005) 2897-2905
121. Asano Y., Ihn H., Yamane K., Jinnin M., and Tamaki K. Increased expression of integrin αvβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 168 (2006) 499-510
122. Sime P.J., Xing Z., Graham F.L., Csaky K.G., and Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100 (1997) 768-776
123. Vallance B.A., Gunawan M.I., Hewlett B., Bercik P., Van Kampen C., Galeazzi F., et al. TGF-β1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 289 (2005) G116-G128
124. McGaha T., Saito S., Phelps R.G., Gordon R., Noben-Trauth N., Paul W.E., et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Rα and transforming growth factor-β genes. J Invest Dermatol 116 (2001) 136-143
125. Lakos G., Takagawa S., Chen S.J., Ferreira A.M., Han G., Masuda K., et al. Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165 (2004) 203-217
126. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194 (2001) 809-821
127. McCormick L.L., Zhang Y., Tootell E., and Gilliam A.C. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163 (1999) 5693-5699
128. Zhang Y., McCormick L.L., and Gilliam A.C. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 121 (2003) 713-719
129. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56 (2007) 323-333
130. Salmon-Ehr V., Serpier H., Nawrocki B., Gillery P., Clavel C., Kalis B., et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132 (1996) 802-806
131. Gruschwitz M.S., Albrecht M., Vieth G., and Haustein U.F. In situ expression and serum levels of tumor necrosis factor-α receptors in patients with early stages of systemic sclerosis. J Rheumatol 24 (1997) 1936-1943
132. Ferrarini M., Steen V., Medsger Jr. T.A., and Whiteside T.L. Functional and phenotypic analysis of T-lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 79 (1990) 346-352
133. Majumdar S., Li D., Ansari T., Pantelidis P., Black C.M., Gizycki M., et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 14 (1999) 251-257
134. Hancock A., Armstrong L., Gama R., and Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18 (1998) 60-65
135. Bolster M.B., Ludwicka A., Sutherland S.E., Strange C., and Silver R.M. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40 (1997) 743-751
136. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42 (1999) 1168-1178
137. Valentini G., Baroni A., Esposito K., Naclerio C., Buommino E., Farzati A., et al. Peripheral blood T-lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21 (2001) 210-217
138. Fujii H., Hasegawa M., Takehara K., Mukaida N., and Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T-lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 130 (2002) 548-556
139. Tsuji-Yamada J., Nakazawa M., Minami M., and Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 28 (2001) 1252-1258
140. Giacomelli R., Cipriani P., Fulminis A., Barattelli G., Matucci-Cerinic M., D'Alò S., et al. Circulating γ/δ T-lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 125 (2001) 310-315
141. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385 (1997) 729-733
142. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370 (1994) 555-557
143. Czirják L., Koncz A., Varga I., Dévényi K., Kumánovics G., and Szücs G. Investigation of the alveolar macrophages and T-lymphocytes in 15 patients with systemic sclerosis. Clin Rheumatol 18 (1999) 357-363
144. Majewski S., Wojas-Pelc A., Malejczyk M., Szymanska E., and Jablonska S. Serum levels of soluble TNFα receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 79 (1999) 207-210
145. Duncan M.R., and Berman B. Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin 1-α and β and tumor necrosis factor-α and β. J Invest Dermatol 92 (1989) 699-706
146. Elias J.A., Freundlich B., Adams S., and Rosenbloom J. Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-γ. Ann NY Acad Sci 580 (1990) 233-244
147. Hetzel M., Bachem M., Anders D., Trischler G., and Faehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung 183 (2005) 225-237
148. Spoelstra F.M., Postma D.S., Hovenga H., Noordhoek J.A., and Kauffman H.F. Interferon-γ and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression on human lung fibroblasts. Eur Respir J 14 (1999) 759-766
149. Ortiz L.A., Lasky J., Lungarella G., Cavarra E., Martorana P., Banks W.A., et al. Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 20 (1999) 825-833
150. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?. Arch Dermatol Res 297 (2006) 333-344
151. Piguet P.F., Kaufman S., Barazzone C., Muller M., Ryffel B., and Eugster H.P. Resistance of TNF/LTα double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol 78 (1997) 43-48
152. Kuroki M., Noguchi Y., Shimono M., Tomono K., Tashiro T., Obata Y., et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 170 (2003) 567-574
153. Allanore Y., Devos-François G., Caramella C., Boumier P., Jounieaux V., and Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65 (2006) 834-835
154. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-γ. Annu Rev Immunol 15 (1997) 749-795
155. Atamas S.P. Complex cytokine regulation of tissue fibrosis. Life Sci 72 (2002) 631-643
156. Scharffetter K., Heckmann M., Hatamochi A., Mauch C., Stein B., Riethmüller G., et al. Synergistic effect of tumor necrosis factor-α and interferon-γ on collagen synthesis of human skin fibroblasts in vitro. Exp Cell Res 181 (1989) 409-419
157. Serpier H., Gillery P., Salmon-Ehr V., Garnotel R., Georges N., Kalis B., et al. Antagonistic effects of interferon-γ and interleukin-4 on fibroblast cultures. J Invest Dermatol 109 (1997) 158-162
158. Morita Y., Yamamura M., Kawashima M., Aita T., Harada S., Okamoto H., et al. Differential in vitro effects of IL-4. IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int 20 (2001) 49-54
159. Oldroyd S.D., Thomas G.L., Gabbiani G., and El Nahas A.M. Interferon-γ inhibits experimental renal fibrosis. Kidney Int 56 (1999) 2116-2127
160. Grassegger A., Schuler G., Hessenberger G., Walder-Hantich B., Jabkowski J., MacHeiner W., et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139 (1998) 639-648
161. Hunzelmann N., Anders S., Fierlbeck G., Hein R., Herrmann K., Albrecht M., et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 133 (1997) 609-613
162. Dinarello C.A. Interleukin-1. Cytok Growth Factor Rev 8 (1997) 253-265
163. Kawaguchi Y., Hara M., and Wright T.M. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 103 (1999) 1253-1260
164. Szegedi A., Czirjak L., Unkeless J.C., and Boros P. Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis. Acta Derm Venereol 76 (1996) 21-23
165. Sasaki M., Kashima M., Ito T., Watanabe A., Izumiyama N., Sano M., et al. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1β and TNF-α. Mediators Inflamm 9 (2000) 155-160
166. Burger D., Rezzonico R., Li J.M., Modoux C., Pierce R.A., Welgus H.G., et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T-lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum 41 (1998) 1748-1759
167. Kawaguchi Y., McCarthy S.A., Watkins S.C., and Wright T.M. Autocrine activation by interleukin 1α induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 31 (2004) 1946-1954
168. Kawaguchi Y., Harigai M., Suzuki K., Hara M., Kobayashi K., Ishizuka T., et al. Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1β. Biochem Biophys Res Commun 190 (1993) 154-161
169. Yamamoto T., Eckes B., Mauch C., Hartmann K., and Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1α loop. J Immunol 164 (2000) 6174-6179
170. Hibi M., Nakajima K., and Hirano T. IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 74 (1996) 1-12
171. Hasegawa M., Sato S., Fujimoto M., Ihn H., Kikuchi K., and Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 25 (1998) 308-313
172. Kadono T., Kikuchi K., Ihn H., Takehara K., and Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 25 (1998) 296-301
173. Takemura H., Suzuki H., Fujisawa H., Yuhara T., Akama T., Yamane K., et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 25 (1998) 1534-1539
174. Maruyama K., Zhang J.Z., Nihei Y., Ono I., and Kaneko F. Regulatory effects of γ-interferon on IL-6 and IL-8 secretion by cultured human keratinocytes and dermal fibroblasts. J Dermatol 22 (1995) 901-906
175. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16 (1998) 495-521
176. Tsuji-Yamada J., Nakazawa M., Takahashi K., Iijima K., Hattori S., Okuda K., et al. Effect of IL-12 encoding plasmid administration on tight-skin mouse. Biochem Biophys Res Commun 280 (2001) 707-712
177. Keane M.P., Belperio J.A., Burdick M.D., and Strieter R.M. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 281 (2001) L92-L97
178. Maeyama T., Kuwano K., Kawasaki M., Kunitake R., Hagimoto N., and Hara N. Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol 280 (2001) L1128-L1137
179. Huaux F., Arras M., Tomasi D., Barbarin V., Delos M., Coutelier J.P., et al. A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J Immunol 169 (2002) 2653-2661
180. Ha S.J., Lee C.H., Lee S.B., Kim C.M., Jang K.L., Shin H.S., et al. A novel function of IL-12p40 as a chemotactic molecule for macrophages. J Immunol 163 (1999) 2902-2908
181. Brown M.A., and Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 17 (1997) 1-32
182. Kolodsick J.E., Toews G.B., Jakubzick C., Hogaboam C., Moore T.A., McKenzie A., et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 172 (2004) 4068-4076
183. Leonardi A., Cortivo R., Fregona I., Plebani M., Secchi A.G., and Abatangelo G. Effects of Th2 cytokines on expression of collagen. MMP-1, and TIMP-1 in conjunctival fibroblasts. Invest Ophthalmol Vis Sci 44 (2003) 183-189
184. Oriente A., Fedarko N.S., Pacocha S.E., Huang S.K., Lichtenstein L.M., and Essayan D.M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292 (2000) 988-994
185. Zhou X., Trudeau J.B., Schoonover K.J., Lundin J.I., Barnes S.M., Cundall M.J., et al. Interleukin-13 augments transforming growth factor-β1-induced tissue inhibitor of metalloproteinase-1 expression in primary human airway fibroblasts. Am J Physiol Cell Physiol 288 (2005) C435-C442
186. Sakkas L.I., Tourtellotte C., Berney S., Myers A.R., and Platsoucas C.D. Increased levels of alternatively spliced interleukin 4 (IL-4δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 6 (1999) 660-664
187. Atamas S.P., and White B. Interleukin 4 in systemic sclerosis: not just an increase. Clin Diagn Lab Immunol 6 (1999) 658-659
188. Kodera T., McGaha T.L., Phelps R., Paul W.E., and Bona C.A. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-β production by fibroblasts. Proc Natl Acad Sci USA 99 (2002) 3800-3805
189. Ong C., Wong C., Roberts C.R., Teh H.S., and Jirik F.R. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 28 (1998) 2619-2629
190. Huaux F., Liu T., McGarry B., Ullenbruch M., and Phan S.H. Dual roles of IL-4 in lung injury and fibrosis. J Immunol 170 (2003) 2083-2092
191. Belperio J.A., Dy M., Burdick M.D., Xue Y.Y., Li K., Elias J.A., et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 27 (2002) 419-427
192. Hasegawa M., Fujimoto M., Kikuchi K., and Takehara K. Elevated serum levels of interleukin 4 (IL-4). IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24 (1997) 328-332
193. Reitamo S., Remitz A., Tamai K., and Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 94 (1994) 2489-2492
194. Yamamoto T., Eckes B., and Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-β and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 281 (2001) 200-205
195. Huaux F., Louahed J., Hudspith B., Meredith C., Delos M., Renauld J.C., et al. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 18 (1998) 51-59
196. Barbarin V., Xing Z., Delos M., Lison D., and Huaux F. Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol 288 (2005) L841-L848
197. Gharaee-Kermani M., and Phan S.H. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 7 (2001) 1083-1103
198. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., and Tamaki K. Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C, a novel growth factor, in human dermal fibroblasts. J Cell Physiol 202 (2005) 510-517
199. Gay S., Jones Jr. R.E., Huang G.Q., and Gay R.E. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92 (1989) 301-303
200. Klareskog L., Gustafsson R., Scheynius A., and Hällgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33 (1990) 1534-1541
201. Barbarin V., Arras M., Misson P., Delos M., McGarry B., Phan S.H., et al. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 31 (2004) 78-85
202. Lobmann R., Pap T., Ambrosch A., Waldmann K., König W., and Lehnert H. Differential effects of PDGF-BB on matrix metalloproteases and cytokine release in fibroblasts of Type 2 diabetic patients and normal controls in vitro. J Diabetes Complications 20 (2006) 105-112
203. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15 (2004) 255-273
204. Hasegawa M., Sato S., and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117 (1999) 159-165
205. Distler O., Rinkes B., Hohenleutner U., Schölmerich J., Landthaler M., Lang B., et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 19 (1999) 39-46
206. Ong V.H., Evans L.A., Shiwen X., Fisher I.B., Rajkumar V., Abraham D.J., et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 48 (2003) 1979-1991
207. Distler O., Pap T., Kowal-Bielecka O., Meyringer R., Guiducci S., Landthaler M., et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44 (2001) 2665-2678
208. Yamamoto T., Eckes B., Hartmann K., and Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 26 (2001) 133-139
209. Carulli M.T., Ong V.H., Ponticos M., Shiwen X., Abraham D.J., Black C.M., et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 52 (2005) 3772-3782
210. Galindo M., Santiago B., Rivero M., Rullas J., Alcami J., and Pablos J.L. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 44 (2001) 1382-1386
211. Yamamoto T., and Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 121 (2003) 510-516
212. Yanaba K., Komura K., Kodera M., Matsushita T., Hasegawa M., Takehara K., et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 65 (2006) 124-126
213. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Xiao H.Q., and White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 26 (2002) 549-557
214. Denton C.P., Shi-Wen X., Sutton A., Abraham D.J., Black C.M., and Pearson J.D. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 114 (1998) 293-300
215. Distler J.H., Jüngel A., Caretto D., Schulze-Horsel U., Kowal-Bielecka O., Gay R.E., et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T-cells. Arthritis Rheum 54 (2006) 214-225
216. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., and Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100 (2002) 1160-1167
217. Yamamoto T., Eckes B., and Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 31 (2001) 2936-2941
218. Galindo M., Santiago B., Alcami J., Rivero M., Martín-Serrano J., and Pablos J.L. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 123 (2001) 36-41
219. Moore B.B., Paine III R., Christensen P.J., Moore T.A., Sitterding S., Ngan R., et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 167 (2001) 4368-4377
220. Zhu Z., Ma B., Zheng T., Homer R.J., Lee C.G., Charo I.F., et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 168 (2002) 2953-2962
221. Herrick A.L., and Worthington J. Genetic epidemiology: systemic sclerosis. Arthritis Res 4 (2002) 165-168
222. Invernizzi P., Miozzo M., Selmi C., Persani L., Battezzati P.M., Zuin M., et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol 175 (2005) 575-578
223. Özbalkan Z., Bagislar S., Kiraz S., Akyerli C.B., Özer H.T., Yavuz S., et al. Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum 52 (2005) 1564-1570
224. Brix T.H., Knudsen G.P., Kristiansen M., Kyvik K.O., Ørstavik K.H., and Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 90 (2005) 5949-5953
225. Ozcelik T., Uz E., Akyerli C.B., Bagislar S., Mustafa C.A., Gursoy A., et al. Evidence from autoimmune thyroiditis of skewed X-chromosome inactivation in female predisposition to autoimmunity. Eur J Hum Genet 14 (2006) 791-797
226. Selmi C., Invernizzi P., and Gershwin M.E. The X chromosome and systemic sclerosis. Curr Opin Rheumatol 18 (2006) 601-605
227. Lunardi C., Bason C., Corrocher R., and Puccetti A. Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol 26 (2005) 19-24
228. Kahaleh M.B., and LeRoy E.C. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31 (1999) 195-214
229. Maricq H.R., Weinrich M.C., Keil J.E., Smith E.A., Harper F.E., Nussbaum A.I., et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 32 (1989) 998-1006
230. Mayes M.D. Scleroderma epidemiology. Rheum Dis Clin North Am 29 (2003) 239-254
231. Arnett F.C., Howard R.F., Tan F., Moulds J.M., Bias W.B., Durban E., et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 39 (1996) 1362-1370
232. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Carzon M., and Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 43 (2004) 1129-1137
233. Allcock R.J., Forrest I., Corris P.A., Crook P.R., and Griffiths I.D. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 43 (2004) 596-602
234. Geirsson A.J., Steinsson K., Guthmundsson S., and Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis 53 (1994) 502-505
235. Alamanos Y., Tsifetaki N., Voulgari P.V., Siozos C., Tsamandouraki K., Alexiou G.A., et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 34 (2005) 714-720
236. Chandran G., Smith M., Ahern M.J., and Roberts-Thomson P.J. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust NZ J Med 25 (1995) 688-694
237. Roberts-Thomson P.J., Walker J.G., Lu T.Y., Esterman A., Hakendorf P., Smith M.D., et al. Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J 36 (2006) 489-497
238. Tamaki T., Mori S., and Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283 (1991) 366-371
239. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30 (2001) 332-346
240. Della Rossa A., Valentini G., Bombardieri S., Bencivelli W., Silman A.J., D'Angelo S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centers. Ann Rheum Dis 60 (2001) 585-591
241. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81 (2002) 139-153
242. Simeón C.P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42 (2003) 71-75
243. Nagy Z., and Czirják L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 16 (1997) 454-460
244. Ioannidis J.P., Vlachoyiannopoulos P.G., Haidich A.B., Medsger Jr. T.A., Lucas M., Michet C.J., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118 (2005) 2-10
245. Trad S., Amoura Z., Beigelman C., Haroche J., Costedoat N., Boutin le T.H., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54 (2006) 184-191
246. Mukerjee D., St. George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
247. Wigley F.M., Lima J.A., Mayes M., McLain D., Chapin J.L., and Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 52 (2005) 2125-2132
248. Mayes M.D., Lacey Jr. J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48 (2003) 2246-2255
249. Lee P., Langevitz P., Alderdice C.A., Aubrey M., Baer P.A., Baron M., et al. Mortality in systemic sclerosis (scleroderma). Q J Med 82 (1992) 139-148
250. Bryan C., Howard Y., Brennan P., Black C., and Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35 (1996) 1122-1126
251. Hesselstrand R., Scheja A., and Åkesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57 (1998) 682-686
252. Jacobsen S., Halberg P., and Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37 (1998) 750-755
253. Nishioka K., Katayama I., Kondo H., Shinkai H., Ueki H., Tamaki K., et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23 (1996) 677-682
254. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., and Tamaki K. Increased expression of integrin αvβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 175 (2005) 7708-7718
255. Asano Y., Ihn H., Yamane K., Kubo M., and Tamaki K. Increased expression levels of integrin αvβ5 on scleroderma fibroblasts. Am J Pathol 164 (2004) 1275-1292
256. Takehara K., Soma Y., Igarashi A., Kikuchi K., Moro A., and Ishibashi Y. Response of scleroderma fibroblasts to various growth factors. Arch Dermatol Res 283 (1991) 461-464
257. Kawakami T., Ihn H., Xu W., Smith E., LeRoy C., and Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 110 (1998) 47-51
258. Pannu J., and Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 16 (2004) 739-745
259. Kawaguchi Y. IL-1α gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol 97 (1994) 445-450
260. Feghali C.A., Bost K.L., Boulware D.W., and Levy L.S. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 19 (1992) 1207-1211
261. Ichiki Y., Smith E., LeRoy E.C., and Trojanowska M. Different effects of basic fibroblast growth factor and transforming growth factor-β on the two platelet-derived growth factor receptors' expression in scleroderma and healthy human dermal fibroblasts. J Invest Dermatol 104 (1995) 124-127
262. Czuwara-Ladykowska J., Gore E.A., Shegogue D.A., Smith E.A., and Trojanowska M. Differential regulation of transforming growth factor-β receptors type I and II by platelet-derived growth factor in human dermal fibroblasts. Br J Dermatol 145 (2001) 569-575